All News

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma Zurich-Schlieren, Switzerland, December 27, 2019. Molecular Partners AG (SIX:MOLN), a clinical stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug [...]

2020-01-06T14:14:02+00:00January 6th, 2020|All News, Company News|

Interview with Bradley Paddock, CEO of CeQur

Interview with Bradley Paddock, CEO of CeQur In June 2019, Bradley Paddock joined CeQur®, as Chief Executive Officer. We spoke to Bradley to hear about his first 6 months in the company and discuss the up-coming U.S. launch of its three-day insulin delivery device for type 2 diabetes.  [...]

2020-01-06T11:51:06+00:00January 6th, 2020|All News, Blog|

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress 2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. - November 11, 2019 - Gynesonics, a women’s healthcare company focused on the development [...]

2019-11-29T16:01:15+00:00November 12th, 2019|All News, Company News|

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year Abicipar [...]

2019-10-22T11:02:49+01:00October 14th, 2019|All News, Company News, Previous Sectors|

V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension

V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension V-Wave’s two distinct FDA Breakthrough Device Designations illustrate the company’s dedication to innovation and improving outcomes for two debilitating diseases – Heart Failure and Pulmonary Arterial Hypertension CAESAREA, Israel, September 12, 2019 – V-Wave Ltd., [...]

2019-10-10T10:05:26+01:00September 13th, 2019|All News, Company News|

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation The acceptance and authorisation are for Abicipar pegol in patients with neovascular (wet) age-related macular degeneration Filing includes data from two Phase 3 trials which evaluated the safety and efficacy [...]

2019-10-10T10:53:56+01:00September 9th, 2019|All News, Company News, Previous Sectors|

Endeavour Vision accelerates investments in Switzerland and the US – an interview with AGEFI

Endeavour Vision accelerates investments in Switzerland and the US – an interview with AGEFI Endeavour Vision Founding Partners Damien Tappy and Bernard Vogel spoke to AGEFI about the next fund and the firm’s investment approach. Read the article from AGEFI here Medtech: Endeavour Vision accélère ses investissements en [...]

2019-10-11T12:00:45+01:00September 9th, 2019|All News, Blog|

Relievant Announces Publication of Positive Results from Multi-Center Study of the Intracept® Procedure in Real-world Setting for Patients with Chronic Low Back Pain

Relievant Announces Publication of Positive Results from Multi-Center Study of the Intracept® Procedure in Real-world Setting for Patients with Chronic Low Back Pain MINNEAPOLIS – August 27, 2019 – Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the [...]

2019-10-10T10:56:03+01:00August 27th, 2019|All News, Company News|

V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure

V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure CAESAREA, Israel, Aug. 15, 2019 — V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted the company a Breakthrough Device [...]

2019-10-10T09:43:56+01:00August 19th, 2019|All News, Company News|